# US 2012/0252718 A1 · Compositions and Methods for Regulating Cytochrome c-Mediated Apoptosis by tRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0252718 A1
- Document ID: US20120252718A1
- Status: Published application
- Kind: A1
- Application number: 13/500,271
- Filed: 2010-10-06
- Published: 2012-10-04
- Earliest claimed: 2009-10-06
- Assignees: The Trustees of the University of Pennsylvania
- Inventors: Xiaolu Yang; Yide Mei; Jeongsik Yong
- Web page: https://patentgrep.com/patent/US20120252718A1

## CPC

- C12N 5/0693: {Tumour cells; Cancer cells}
- A61K 38/02: Peptides of undefined number of amino acids; Derivatives thereof
- A61K 38/43: Enzymes; Proenzymes; Derivatives thereof
- C12N 5/0602: {Vertebrate cells}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 2501/06: Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
- C12N 2501/73: Hydrolases (EC 3.)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the discovery that tRNA is a potent regulator of cell survival, tRNA regulates the interaction between cytochrome c and Apaf-1 and subsequently Apaf-1 oligomerization into an apoptosome which in turn recruits and oligomerizes the caspase cascade which ultimately leads to cell death. Accordingly, the present invention provides compositions and methods for regulating cell survival.

## Claims

### Claim 1

A method of enhancing survival of a cell, said method comprising inhibiting the formation of an apoptosome in a cell by contacting said cell with an effective amount of a tRNA activator, wherein when said tRNA activator contacts said cell, said tRNA activator increases the expression function, stability, or activity of said tRNA, wherein said tRNA binds to cytochrome c, thereby enhancing survival of said cell.

### Claim 2 (depends on 1)

The method of claim 1, wherein said cell is a mammalian cell.

### Claim 3 (depends on 2)

The method of claim 2, wherein said cell is a human cell.

### Claim 4

A method of inhibiting survival of a cell, said method comprising enhancing formation of an apoptosome in a cell by contacting said cell with an effective amount of a tRNA inhibitor, wherein when said tRNA inhibitor contacts said cell, said tRNA inhibitor decreases expression, function, stability, or activity of said tRNA, wherein said tRNA does not bind to cytochrome c, thereby inhibiting survival of said cell.

### Claim 5 (depends on 4)

The method of claim 4, wherein said tRNA inhibitor is selected from the group consisting of a protein, a peptide, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, or any combination thereof.

### Claim 6 (depends on 4)

The method of claim 4, wherein said cell is a mammalian cell.

### Claim 7 (depends on 6)

The method of claim 6, wherein said mammalian cell is a human cell.

### Claim 8 (depends on 7)

The method of claim 7, wherein said human cell is a cancer cell.

### Claim 9 (depends on 5)

The method of claim 5, wherein said protein is an RNase.

### Claim 10 (depends on 9)

The method of claim 9, wherein said RNase is onconase.

### Claim 11 (depends on 4)

The method of claim 4, wherein said tRNA inhibitor is administered in combination with a therapeutically effective amount of another therapeutic agent.

### Claim 12 (depends on 11)

The method of claim 11, wherein said therapeutic agent is doxorubicin.

### Claim 13

A method of augmenting tRNA expression, function or activity in a cell, said method comprising contacting said cell with a tRNA activator, wherein when said tRNA activator contacts said cell, said tRNA activator augments said tRNA expression, function, or activity in said cell, wherein said tRNA does not bind to cytochrome c, thereby inhibiting survival of said cell.

### Claim 14 (depends on 13)

The method of claim 13, wherein said tRNA activator is selected from the group consisting of a protein, a peptide, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, or any combination thereof.

### Claim 15 (depends on 13)

The method of claim 13, wherein said cell is a mammalian cell.

### Claim 16 (depends on 15)

The method of claim 15, wherein said mammalian cell is a human cell.

### Claim 17

A method of inhibiting tRNA expression, function or activity in a cell, said method comprising contacting a cell with a tRNA inhibitor, wherein when said tRNA inhibitor contacts said cell, said tRNA inhibitor reduces said tRNA expression, function, or activity in said cell, wherein said tRNA does not bind cytochrome c, thereby inhibiting survival of said cell.

### Claim 18 (depends on 17)

The method of claim 17, wherein said tRNA inhibitor is selected from the group consisting of a protein, a peptide, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, or any combination thereof.

### Claim 19 (depends on 17)

The method of claim 17, wherein said cell is a mammalian cell.

### Claim 20 (depends on 19)

The method of claim 19, wherein said cell mammalian cells is a human cell.

### Claim 21

A method of inhibiting an interaction between cytochrome c and Apaf-1 in a cell, said method comprising contacting said cell with an effective amount of a tRNA activator, wherein said tRNA activator increases tRNA expression, activity, stability, or function in said cell, thereby inhibiting said interaction between cytochrome c and Apaf-1 and enhancing cell survival.

### Claim 22 (depends on 21)

The method of claim 21, wherein said tRNA activator is selected from the group consisting of a protein, a peptide, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, or any combination thereof.

### Claim 23 (depends on 21)

The method of claim 21, wherein said cell is a mammalian cell.

### Claim 24 (depends on 23)

The method of claim 23, wherein said mammalian cell is a human cell.

### Claim 25

A method of increasing an interaction between cytochrome c and Apaf-1 in a cell, said method comprising contacting said cell with an effective amount of a tRNA inhibitor, wherein said tRNA inhibitor increases tRNA expression, activity, stability, or function in said cell, thereby increasing said interaction between cytochrome c and Apaf-1, thereby decreasing cell survival.

### Claim 26 (depends on 25)

The method of claim 25, wherein said tRNA inhibitor is selected from the group consisting of a protein, a peptide, an siRNA, a ribozyme, an antisense, an aptamer, a peptidomimetic, a small molecule, or any combination thereof.

### Claim 27 (depends on 25)

The method of claim 25, wherein said cell is a mammalian cell.

### Claim 28 (depends on 27)

The method of claim 27, wherein said cell is a human cell.

### Claim 29

A method of treating a disease associated with aberrant cytochrome c release in a mammal, the method comprising administering to a mammal in need thereof a composition comprising a tRNA activator or a tRNA inhibitor.
